Pantoprazole and Transitional cell carcinoma - a phase IV clinical study of FDA data

Summary:

Transitional cell carcinoma is reported as a side effect among people who take Pantoprazole (pantoprazole sodium), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Aspirin, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Transitional cell carcinoma when taking Pantoprazole. It is created by eHealthMe based on reports of 281,696 people who have side effects when taking Pantoprazole from the FDA, and is updated regularly.

What is Pantoprazole?

Pantoprazole has active ingredients of pantoprazole sodium. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 285,170 Pantoprazole users. Check the latest studies of Pantoprazole.

What is Transitional cell carcinoma?

Transitional cell carcinoma (cancer tumour inner most layer of urinary system) is found to be associated with 186 drugs and 268 conditions by eHealthMe. Check the latest studies of Transitional cell carcinoma.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

281,696 people reported to have side effects when taking Pantoprazole.
Among them, 42 people (0.01%) have Transitional cell carcinoma.

Could Pantoprazole cause Transitional cell carcinoma?

Among these 42 people:

How long have people been on Pantoprazole when they have Transitional cell carcinoma? *

What is the gender of people who have Transitional cell carcinoma when taking Pantoprazole? *

female: 12.5 %
male: 87.5 %

What is the age of people who have Transitional cell carcinoma when taking Pantoprazole? *

What are other drugs people take besides Pantoprazole? *

What are other side effects people have besides Transitional cell carcinoma? *

Splenomegaly (enlargement of spleen): 5 people, 11.90%
Pain: 4 people, 9.52%
Gallstones (stone formation by bile component): 4 people, 9.52%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 4 people, 9.52%
Myocardial Ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased): 4 people, 9.52%
Drowsiness: 4 people, 9.52%
Septic Shock (shock due to blood infection): 4 people, 9.52%
Memory Loss: 4 people, 9.52%
Pseudomonal Bacteraemia (p. aeruginosa cause of bacterial infections of the blood): 4 people, 9.52%
Malaise (a feeling of general discomfort or uneasiness): 4 people, 9.52%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 16 people, 38.10%
High Blood Pressure: 7 people, 16.67%
Salivary Hypersecretion (excess saliva secretion): 4 people, 9.52%
Depression: 4 people, 9.52%
Itching: 4 people, 9.52%
Dyspnea (difficult or laboured breathing): 4 people, 9.52%
Burkitt Lymphoma (cancer of the lymphatic system): 3 people, 7.14%
High Blood Cholesterol: 3 people, 7.14%
Type 2 Diabetes: 3 people, 7.14%
Indigestion: 3 people, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Pantoprazole and have Transitional cell carcinoma?

- Check whether Transitional cell carcinoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Pantoprazole:

Pantoprazole (285,170 reports)

Browse all side effects of Pantoprazole:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Transitional cell carcinoma:

Transitional cell carcinoma (186 drugs)

Browse all the conditions that are associated with Transitional cell carcinoma:

Transitional cell carcinoma (268 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pantoprazole sodium (the active ingredients of Pantoprazole) and Pantoprazole (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.